Gelteq Limited Ordinary Shares Net Assets
Gelteq Limited Ordinary Shares net assets. Based on the latest financial reports, Gelteq Limited Ordinary Shares (GELS) has net assets worth $14.20 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.13 Million) and total liabilities ($5.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Gelteq Limited Ordinary Shares (GELS) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.20 Million |
| % of Total Assets | 70.57% |
| Annual Growth Rate | 134.49% |
| 5-Year Change | -33.64% |
| 10-Year Change | N/A |
| Growth Volatility | 4234.23 |
Net Assets of Gelteq Limited Ordinary Shares (2020–2025)
Net assets of Gelteq Limited Ordinary Shares from 2020 to 2025. This chart illustrates how Gelteq Limited Ordinary Shares's net assets have evolved over time, based on quarterly financial data. See GELS equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Gelteq Limited Ordinary Shares (2020–2025)
The table below shows the annual net assets of Gelteq Limited Ordinary Shares from 2020 to 2025. For live market cap and overall valuation, see Gelteq Limited Ordinary Shares (GELS) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $15.80 Million | +4.58% |
| 2024-06-30 | $15.11 Million | -19.01% |
| 2023-06-30 | $18.66 Million | -10.53% |
| 2022-06-30 | $20.86 Million | -12.43% |
| 2021-06-30 | $23.82 Million | +10576.22% |
| 2020-06-30 | $223.07K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gelteq Limited Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1768095800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Gelteq Limited Ordinary Shares Net Assets Breakdown (June 2025)
Gelteq Limited Ordinary Shares net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $33.95 Million | 214.79% |
| Total Equity | $15.80 Million | 100.00% |
Gelteq Limited Ordinary Shares Competitors by Market Cap
The table below lists competitors of Gelteq Limited Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intertainment AG
XETRA:ITN
|
$5.24 Million |
|
Combigene AB
ST:COMBI
|
$5.24 Million |
|
Bhakti Agung Propertindo
JK:BAPI
|
$5.24 Million |
|
VIA OPTRONICS AG SP.ADS/1
F:5UU1
|
$5.24 Million |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
$5.24 Million |
|
Union Pioneer Public Company Limited
BK:UPF
|
$5.24 Million |
|
ENEFI Energiahatekonysagi Nyrt
BUD:ENEFI
|
$5.24 Million |
|
Shiva Mills Limited
NSE:SHIVAMILLS
|
$5.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gelteq Limited Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,112,297 to 15,804,486, a change of 692,189 (4.6%).
- Net loss of 6,645,453 reduced equity.
- New share issuances of 7,913,463 increased equity.
- Other factors decreased equity by 575,821.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.65 Million | -42.05% |
| Share Issuances | $7.91 Million | +50.07% |
| Other Changes | $-575.82K | -3.64% |
| Total Change | $- | 4.58% |
Book Value vs Market Value Analysis
This analysis compares Gelteq Limited Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.15x to 0.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | $0.10 | $0.49 | x |
| 2021-06-30 | $2.52 | $0.49 | x |
| 2022-06-30 | $2.21 | $0.49 | x |
| 2023-06-30 | $1.98 | $0.49 | x |
| 2024-06-30 | $1.60 | $0.49 | x |
| 2025-06-30 | $1.58 | $0.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gelteq Limited Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4011.86%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.36x
- Recent ROE (-42.05%) is above the historical average (-45.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -168.37% | 0.00% | 0.00x | 2.78x | $-397.89K |
| 2021 | -2.72% | 0.00% | 0.00x | 1.02x | $-3.03 Million |
| 2022 | -16.15% | -2283.44% | 0.01x | 1.12x | $-5.45 Million |
| 2023 | -18.79% | -4391.39% | 0.00x | 1.21x | $-5.37 Million |
| 2024 | -23.47% | 0.00% | 0.00x | 1.37x | $-5.06 Million |
| 2025 | -42.05% | -4011.86% | 0.01x | 1.36x | $-8.23 Million |
Industry Comparison
This section compares Gelteq Limited Ordinary Shares's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $86,713,726
- Average return on equity (ROE) among peers: 26.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $14.20 Million | -168.37% | 0.42x | $5.24 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $335.50 Million | -73.41% | 0.53x | $143.73 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $584.11K |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $194.43 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.67 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.25 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $5.96 Million | 1208.40% | 615.85x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $135.63 Million | 15.17% | 0.15x | $260.30 Million |
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Austra… Read more